Addition o f E ither L onidamine o r G ranulocyte Colony-Stimulati ng F actor D oes N ot I mprove S urvival i n E arly Breast C ancer P atients T reated W ith H igh-Dose E pirubicin and C yclophosphamide
Paola Papaldo(Cancer Institute (WIA)), Paolo Marolla(Catholic University of America), Claudio Botti(Catholic University of America), Paolo Carlini(National Cancer Institute), E. Terzoli(Catholic University of America), Cecilia Nisticò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Alessandra Fabi(Agostino Gemelli University Polyclinic), Carlo Vitucci(Molecular Oncology (United States)), Eugenio Cammilluzzi(Molecular Oncology (United States)), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Giuseppe Lepidini(Molecular Oncology (United States)), Mauro Antimi(Catholic University of America), Diana Giannarelli(Agostino Gemelli University Polyclinic), Enrico Cortesi(Sapienza University of Rome), Francesca Conti(Catholic University of America), Patrizia Vici(Istituti di Ricovero e Cura a Carattere Scientifico), Massimo Lopez(Catholic University of America), Carlo Barone(Università Cattolica del Sacro Cuore)
Unknown
January 1, 2003
Cited by 0
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
|New England Journal of Medicine|2014|1.1k
Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
|JAMA Oncology|2018|418